The effect of low dose (50 KIU/ml) and high dose (200 KIU/ml) aprotinin on standard thrombelastographic variables (r, K, α, MA) was examined in vitro using blood from forty ASA Class I patients. Both concentrations of aprotinin resulted in minor increases in r time above the normal range (P<0.05). Aprotinin did not alter other thrombelastographic variables. The results indicate that aprotinin is a mild direct anticoagulant in vitro as assessed by thrombelastography.
Aprotinin (Bayer AG, Germany) is a serine protease inhibitor that reduces blood loss during major surgical procedures such as liver transplantation and coronary artery bypass grafting 1, 2 . The haemostatic effects of aprotinin appear to be indirect, involving protection of platelets as well as inhibition of plasmin and kallikrein 3 . In contrast, the direct effect of aprotinin may be anticoagulant 3 .
Thrombelastography (TEG) is often used to monitor coagulation during major surgical procedures 4 . At present, the direct effect of aprotinin on the TEG during these procedures is not known. Aprotinin may have an overall procoagulant effect as observed in vivo. Alternatively, aprotinin may have an anticoagulant effect which would confound the interpretation of the TEG. Another possibility is that aprotinin has different effects at low and high doses. A previous study found that aprotinin markedly altered TEG patterns in vitro during the anhepatic phase of liver transplantation 5 . However, most of the patients studied had an underlying hypocoagulable state or fibrinolysis.Therefore this finding may not apply to patients who have normal coagulation preoperatively.
The aim of the current study was to examine the direct effect of low-dose and high-dose aprotinin on TEG variables in healthy awake patients in vitro.
METHOD
The study was approved by the Human Rights Committee of the University of Western Australia. Informed consent was obtained from all patients who participated. Forty adult ASA Class I patients undergoing elective surgery were recruited. None of the patients was taking medication known to affect coagulation or platelet function. Patients received either no premedication, or oral temazepam 10 to 20 mg one hour preoperatively. Venous blood samples (4 ml) were obtained from each patient prior to the induction of anaesthesia. The first 2 ml collected was discarded. The second 2 ml was placed in a plastic collection tube. Four minutes after collection, 350 µl aliquots were placed in each cup of a two-channel computerized TEG (Haemoscope, Skokie, IL, U.S.A.). Aprotinin 10 µl was added to the 'test' channel, and 10 µl normal saline (NS) was added to the 'control' channel. The concentration of the added aprotinin was adjusted (by dilution with NS) to provide final concentrations in the test TEG cups of 50 kallikrein inhibition units (KIU) per ml (n=20, low dose; group 1) or 200 KIU/ml (n=20, high dose; group 2). The final concentrations chosen were the target concentrations required to inhibit plasmin (50 KIU/ml, low dose) and kallikrein (200 KIU/ml, high dose) in pure chemical systems in vitro 6 . The r (reaction) time, K (coagulation) time, α angle, and maximum amplitude (MA) were recorded for each channel. The test and control values at each concentration were compared using Wilcoxon's signed rank test with α=0.05.
RESULTS
Group 1 had a mean age of 40.8 years (range 18-76) and male:female ratio of 13:7. Group 2 was similar with a mean age of 35.0 years (18-65) and a male:female ratio of 10:10. The control and test data are given in Table 1 . There were minor increases in r time above the normal range in both the low-dose (50 KIU/ml) and the high-dose (200 KIU/ml) groups (P<0.05). There were no significant changes in K time, α angle, or MA in either group. A typical effect of aprotinin 200 KIU on the TEG is displayed in Figure 1 .
DISCUSSION
The results indicate that aprotinin is a mild direct anticoagulant in vitro as assessed by thrombelastography. Both the 50 KIU/ml and the 200 KIU/ml concentrations are associated with minor, but statistically significant increases in r time above the normal range. The magnitude of the increases (20-30%) would be unlikely to be important clinically. There were no changes in K time, α angle or MA. The r time is an index of the time taken to the onset of fibrin formation, which depends on the activation of clotting factors 4 . The α angle and K time are indices of the rate of clot formation, and the MA is an index of the maximum strength of the clot 4 . As such, the results indicate that aprotinin inhibits the initial activation of clotting factors in vitro, but not the rate of subsequent clot formation or clot strength.
The 50 KIU/ml and 200 KIU/ml concentrations used in this study are equivalent to the target concentrations for low-dose and high-dose aprotinin regimens perioperatively. These concentrations are based on the inhibition of plasmin and kallikrein in pure chemical systems in vitro 6 . Standard therapeutic doses of aprotinin 500,000 KIU and 1,000,000 KIU result in peak plasma levels of about 60 KIU/ml and 147 KIU/ml respectively 7 . As such, the concentrations used in this study are similar to those obtained clinically. However, the results do not apply to aprotinin levels outside this range.
Although there were no significant changes in K time, α angle, or MA, a true difference in one or more of these variables cannot be excluded due to the possibility of a type II error. Nevertheless, there did not appear to be a trend to increased or decreased values of these variables at either concentration. No attempt was made to compare data between low-dose and high-dose groups, due to the inadequate sample size for such a comparison.
Studies involving coagulation are often difficult to analyse due to interpatient variability and a wide range of normal values. The manufacturer's normal range for TEG values (Table 1) includes only one standard deviation about the mean 8 . If two standard deviations are used, the 'normal' range is much wider. Indeed, many of our patients' control values fell within this larger range. In the current study, interpatient variability was avoided by obtaining control and test samples from the same patient. Similarly, differences in activation of coagulation factors and platelets were avoided by collecting both samples at the same time, through the same venepuncture, and analysing them simultaneously on a two channel TEG. In this way it was possible to detect minor changes in the TEG.
An in vitro technique was chosen to avoid other factors that may influence coagulation. Surgery results in a stress response that affects many processes including coagulation 9 . Moreover, patients undergoing major surgery may be taking other drugs known to affect haemostasis. In addition, surgical patients receive many other drugs such as anaesthetic agents and antibiotics, and often require intravenous fluid or blood. Therefore, it may be difficult to identify minor 553 TEG EFFECTS OF APROTININ Anaesthesia and Intensive Care, Vol. 24, No. 5, October 1996 FIGURE 1: Typical effect of aprotinin 200 KIU/ml on the thrombelastograph. r=time between onset and 2 mm divergence; K=time between 2 mm and 20 mm divergence (note that the thrombelastograph runs at 2 mm/min); α=angle between the horizontal and a line drawn from the point of 2 mm divergence to the shoulder of the trace; The maximum amplitude is the maximum divergence. effects of a single drug in a clinical setting. In particular, it is not possible to differentiate between direct and indirect effects in vivo.
The finding of a direct anticoagulant effect of aprotinin in vitro does not necessarily imply a direct anticoagulant effect in vivo. Coagulation in vivo involves the dynamic interaction of many factors including the vessel wall. Nevertheless, the results support the view that the direct effects of aprotinin are anticoagulant rather than procoagulant 3 .
Aprotinin is often given to patients with normal coagulation to prevent the development of a coagulation disturbance during major surgery or cardiopulmonary bypass 4 . The results indicate that a minor increase in the TEG r time may occur in these patients. However, more marked TEG changes involving α angle, K time and MA should not be attributed to the effects of aprotinin alone. Therefore the TEG may still provide useful information in patients receiving aprotinin. The results may not apply to patients who have already developed a coagulopathy, who may respond to aprotinin in a different manner. Further studies are required to fully characterize the direct effect of aprotinin in these patients.
